Glucogast (Fludeoxyglucose (18f))

Glucogast is indicated for several PET imaging applications where assessment of cellular glucose metabolism is required.

• Oncologic PET imaging to detect, stage, and monitor malignant tumors.
• Cardiac PET imaging to evaluate myocardial viability and perfusion.
• Neurologic PET imaging for assessment of epilepsy, dementia, and brain metabolism disorders.
• Research studies investigating metabolic pathways or therapeutic response.

Adverse reactions to Glucogast are generally infrequent and related to the radiopharmaceutical nature of the product.

Common

• Transient flushing or warmth at the injection site.
• Mild nausea or vomiting.
• Short‑lasting headache.
• Temporary metallic taste in the mouth.

Serious

• Allergic reactions such as urticaria, angioedema, or anaphylaxis.
• Significant radiation‑induced tissue injury in rare cases.
• Severe hypotension or cardiovascular collapse.
• Persistent neurologic symptoms.

Use of Glucogast requires careful consideration of patient condition, radiation safety, and procedural factors.

• Verify pregnancy status; the radiopharmaceutical may pose fetal risk.
• Assess renal function, as impaired clearance can increase radiation exposure.
• Ensure adequate hydration before and after administration to promote tracer elimination.
• Observe patients for immediate hypersensitivity reactions during and after injection.
• Follow local radiation protection guidelines for staff and environment.
• Avoid use in patients with uncontrolled diabetes unless glucose levels are appropriately managed.

Glucogast may interact with other agents that affect glucose metabolism or radiation exposure.

Avoid

• Concurrent administration of high‑dose glucose or insulin that could alter tracer distribution.
• Use of other radiopharmaceuticals within 24 hours, which may increase cumulative radiation dose.

Use with caution

• Medications that cause vasodilation or hypotension, which may exacerbate rare cardiovascular reactions.
• Contrast agents used in CT imaging performed immediately after PET, due to potential additive radiation.
• Antihistamines or corticosteroids may mask early signs of an allergic response.